The VO2 Increase With Testosterone Addition - Heart Failure (VITA-HF) Trial

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It plans to enroll 318 participants.

Also called NCT01469988

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 318 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01469988
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01469988. Randomized; double masking; primary purpose treatment. Start 2012-11 (registry gives no type); primary completion 2014-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The VO2 Increase With Testosterone Addition - Heart Failure (VITA-HF) Trial
Acronym
VITA-HF
Condition
Heart Failure
Intervention (Drug)
Testosterone
Lead sponsor
University of Alberta (class: other)

Record details

Record id
cardio:ct-nct01469988
Content hash
d2f9db37db907be94e02bc5b1c6c79c155b4d4c5ad9cea5173da951cb9e836c1